BMO Capital analyst Kostas Biliouris raised the firm’s price target on Centessa to $15 from $11 and keeps an Outperform rating on the shares. The analyst cites the firm’s recent talks with the management on ORX750, stating that based on preclinical data and commentary, BMO believes that the drug has the potential to deliver a best-in-class profile in Narcolepsy and other applicable indications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNTA: